{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:36:51Z","timestamp":1788050211653,"version":"build-2784847793"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":200,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Huntington\u2019s disease is an inherited neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene, encoding an expanded polyglutamine tract in the huntingtin (HTT) protein. The pathogenic CAG repeat of HTT is unstable and undergoes progressive somatic expansion in specific brain cells and peripheral tissues throughout life. Genes involved in DNA mismatch repair pathways, which promote repeat expansion, have been identified as genetic modifiers of the disease. Consequently, the rate of CAG repeat expansion is a key determinant driving the age of onset and disease progression. As the CAG repeat expands, alternative processing of HTT pre-mRNA increasingly favours production of the HTT1a transcript, which encodes the highly pathogenic and aggregation-prone HTT1a protein. This process provides a mechanistic link between CAG repeat expansion and disease pathogenesis, as increased HTT1a production accelerates HTT aggregation and neuronal dysfunction. HTT1a has previously been detected in Huntington\u2019s disease mouse models by using immunoprecipitation coupled with western blotting, homogeneous time-resolved fluorescence (HTRF) and Meso Scale Discovery (MSD) bioassays and immunohistochemistry. These approaches were developed using MW8, a neoepitope antibody that specifically recognizes the C-terminus of HTT1a. MW8 is a relatively weak antibody with limited detection sensitivity. To generate more robust HTT1a-specific reagents, two novel recombinant antibodies, 1B12 and 11G2, have been developed for evaluation. Using an allelic series of knock-in (HdhQ20, HdhQ50, HdhQ80, HdhQ111, CAG140 and zQ175) mice, alongside transgenic YAC128 and N171-82Q models, we extensively evaluated and compared the performance of MW8, 1B12 and 11G2. We demonstrate that 1B12 and 11G2 function as HTT1a-specific neoepitope antibodies by immunoprecipitation with western blotting and by immunohistochemistry. To enhance HTT1a detection using HTRF and MSD technology platforms, we further evaluated the performance of 1B12 and 11G2 in HTT bioassays using cortical lysates from zQ175 and YAC128 mice. In zQ175 mice, enhanced detection of aggregated HTT1a by HTRF and MSD revealed that HTT fragments longer than HTT1a can be incorporated into HTT1a-containing aggregates. The most sensitive assays were subsequently applied across the allelic series of knock-in mice to assess the effect of polyglutamine length on bioassay performance. For optimal sensitivity, we recommend the preferential use of 1B12 for HTRF assays and 11G2 for MSD assays. Collectively, these findings establish 1B12 and 11G2 as robust antibodies to reliably detect and track HTT1a pathology in vivo and promote the replacement of previously used MW8-based experimental approaches.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag285","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:39:27Z","timestamp":1784374767000},"source":"Crossref","is-referenced-by-count":1,"title":["Enhancing the detection of HTT1a with neoepitope antibodies in mouse models of Huntington\u2019s disease"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-3179","authenticated-orcid":false,"given":"Georgina F","family":"Osborne","sequence":"first","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-7575","authenticated-orcid":false,"given":"Edward J","family":"Smith","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirupa","family":"Sathasivam","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9275-7709","authenticated-orcid":false,"given":"Zixin","family":"Kang","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4745-0816","authenticated-orcid":false,"given":"Iulia M","family":"Nita","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7080-1221","authenticated-orcid":false,"given":"Mar\u00eda","family":"Ca\u00f1ibano-Pico","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8019-6703","authenticated-orcid":false,"given":"Jemima","family":"Phillips","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-6305","authenticated-orcid":false,"given":"Gillian P","family":"Bates","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-6447","authenticated-orcid":false,"given":"Christian","family":"Landles","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026080309063100200_fcag285-B1","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2026080309063100200_fcag285-B2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"issue":"4","key":"2026080309063100200_fcag285-B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington's disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat Genet"},{"issue":"1","key":"2026080309063100200_fcag285-B4","first-page":"16","article-title":"Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am J Hum Genet"},{"issue":"10","key":"2026080309063100200_fcag285-B5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/2.10.1535","article-title":"Molecular analysis of juvenile Huntington disease: The major influence on (CAG)n repeat length is the sex of the affected parent","volume":"2","author":"Telenius","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"7","key":"2026080309063100200_fcag285-B6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington\u2019s disease: Lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"2026080309063100200_fcag285-B7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ng0494-409","article-title":"Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm","volume":"6","author":"Telenius","year":"1994","journal-title":"Nat Genet"},{"issue":"24","key":"2026080309063100200_fcag285-B8","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","article-title":"Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis","volume":"12","author":"Kennedy","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2026080309063100200_fcag285-B9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41588-024-01653-6","article-title":"Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum","volume":"56","author":"M\u00e4tlik","year":"2024","journal-title":"Nat Genet"},{"issue":"3","key":"2026080309063100200_fcag285-B10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cell.2024.11.038","article-title":"Long somatic DNA-repeat expansion drives neurodegeneration in Huntington\u2019s disease","volume":"188","author":"Handsaker","year":"2025","journal-title":"Cell"},{"issue":"3","key":"2026080309063100200_fcag285-B11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington\u2019s disease","volume":"162","author":"Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium","year":"2015","journal-title":"Cell"},{"issue":"4","key":"2026080309063100200_fcag285-B12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset","volume":"178","author":"Genetic Modifiers of Huntington\u2019s Disease (Gem-HD) Consortium","year":"2019","journal-title":"Cell"},{"issue":"9","key":"2026080309063100200_fcag285-B13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: A genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol"},{"issue":"19","key":"2026080309063100200_fcag285-B14","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/hmg\/ddx286","article-title":"A modifier of Huntington\u2019s disease onset at the MLH1 locus","volume":"26","author":"Lee","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2026080309063100200_fcag285-B15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/hmg\/ddm054","article-title":"Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain","volume":"16","author":"Shelbourne","year":"2007","journal-title":"Hum Mol Genet"},{"key":"2026080309063100200_fcag285-B16","first-page":"924","author":"Pressl","year":"2024"},{"issue":"6","key":"2026080309063100200_fcag285-B17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026080309063100200_fcag285-B18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","article-title":"The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients","volume":"7","author":"Neueder","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2026080309063100200_fcag285-B19","doi-asserted-by":"crossref","first-page":"16137","DOI":"10.1038\/s41598-019-52411-2","article-title":"Extensive expression analysis of Htt transcripts in brain regions from the zQ175 HD mouse model using a QuantiGene multiplex assay","volume":"9","author":"Papadopoulou","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"2026080309063100200_fcag285-B20","doi-asserted-by":"crossref","first-page":"fcae410","DOI":"10.1093\/braincomms\/fcae410","article-title":"Mutant huntingtin protein decreases with CAG repeat expansion: Implications for therapeutics and bioassays","volume":"6","author":"Landles","year":"2024","journal-title":"Brain Commun"},{"key":"2026080309063100200_fcag285-B21","doi-asserted-by":"crossref","first-page":"awag040","DOI":"10.1093\/brain\/awag040","article-title":"The HTT1a protein initiates HTT aggregation in a knock-in mouse model of Huntington\u2019s disease","author":"Papadopoulou","year":"2026","journal-title":"Brain"},{"issue":"1","key":"2026080309063100200_fcag285-B22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ab.2009.08.001","article-title":"Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington\u2019s disease","volume":"395","author":"Weiss","year":"2009","journal-title":"Anal Biochem"},{"issue":"2","key":"2026080309063100200_fcag285-B23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.chembiol.2011.12.020","article-title":"TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington\u2019s disease","volume":"19","author":"Baldo","year":"2012","journal-title":"Chem Biol"},{"issue":"1","key":"2026080309063100200_fcag285-B24","doi-asserted-by":"crossref","first-page":"fcaa231","DOI":"10.1093\/braincomms\/fcaa231","article-title":"Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms","volume":"3","author":"Landles","year":"2021","journal-title":"Brain Commun"},{"issue":"5","key":"2026080309063100200_fcag285-B25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096854","article-title":"Quantification assays for total and polyglutamine-expanded huntingtin proteins","volume":"9","author":"Macdonald","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2026080309063100200_fcag285-B26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213521","article-title":"Meso scale discovery-based assays for the detection of aggregated huntingtin","volume":"14","author":"Reindl","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"2026080309063100200_fcag285-B27","doi-asserted-by":"crossref","first-page":"ENEURO.0234-18.2018","DOI":"10.1523\/ENEURO.0234-18.2018","article-title":"Quantification of total and mutant huntingtin protein levels in biospecimens using a novel alphaLISA assay","volume":"5","author":"Baldo","year":"2018","journal-title":"eNeuro"},{"issue":"4","key":"2026080309063100200_fcag285-B28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JHD-170269","article-title":"Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay","volume":"6","author":"Fodale","year":"2017","journal-title":"J Huntingtons Dis"},{"issue":"5","key":"2026080309063100200_fcag285-B29","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"2026080309063100200_fcag285-B30","doi-asserted-by":"crossref","first-page":"fcad010","DOI":"10.1093\/braincomms\/fcad010","article-title":"Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approaches","volume":"5","author":"Smith","year":"2023","journal-title":"Brain Commun"},{"issue":"12","key":"2026080309063100200_fcag285-B31","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","article-title":"Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease","volume":"285","author":"Landles","year":"2010","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"2026080309063100200_fcag285-B32","first-page":"A32.2","article-title":"Development of an HTT exon1-selective MSD immunoassay with novel HTT P90 neo-epitope-specific antibodies","volume":"95","author":"Baldo","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2026080309063100200_fcag285-B33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/hmg\/8.1.115","article-title":"Length-dependent gametic CAG repeat instability in the Huntington\u2019s disease knock-in mouse","volume":"8","author":"Wheeler","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2026080309063100200_fcag285-B34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"2026080309063100200_fcag285-B35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050717","article-title":"Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease","volume":"7","author":"Heikkinen","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"2026080309063100200_fcag285-B36","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1093\/brain\/awac241","article-title":"Alternative processing of human HTT mRNA with implications for Huntington\u2019s disease therapeutics","volume":"145","author":"Fienko","year":"2022","journal-title":"Brain"},{"issue":"1","key":"2026080309063100200_fcag285-B37","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1038\/s41598-020-71111-w","article-title":"Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington\u2019s disease models","volume":"10","author":"Mason","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"2026080309063100200_fcag285-B38","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/dds037","article-title":"Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice","volume":"21","author":"Pouladi","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2026080309063100200_fcag285-B39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2026080309063100200_fcag285-B40","doi-asserted-by":"crossref","first-page":"fcaa066","DOI":"10.1093\/braincomms\/fcaa066","article-title":"Subcellular localization and formation of huntingtin aggregates correlates with symptom onset and progression in a Huntington\u2019s disease model","volume":"2","author":"Landles","year":"2020","journal-title":"Brain Commun"},{"issue":"4","key":"2026080309063100200_fcag285-B41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"5","key":"2026080309063100200_fcag285-B42","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/brain\/awae063","article-title":"A CAG repeat threshold for therapeutics targeting somatic instability in Huntington\u2019s disease","volume":"147","author":"Aldous","year":"2024","journal-title":"Brain"},{"issue":"3-4","key":"2026080309063100200_fcag285-B43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0361-9230(01)00599-8","article-title":"New anti-huntingtin monoclonal antibodies: Implications for huntingtin conformation and its binding proteins","volume":"56","author":"Ko","year":"2001","journal-title":"Brain Res Bull"},{"issue":"1","key":"2026080309063100200_fcag285-B44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol"},{"issue":"1","key":"2026080309063100200_fcag285-B45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0896-6273(00)80839-9","article-title":"Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA","volume":"24","author":"Schilling","year":"1999","journal-title":"Neuron"},{"issue":"13","key":"2026080309063100200_fcag285-B46","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"841","key":"2026080309063100200_fcag285-B47","doi-asserted-by":"crossref","first-page":"eadv0702","DOI":"10.1126\/scitranslmed.adv0702","article-title":"Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington\u2019s disease mice","volume":"18","author":"Bragg","year":"2026","journal-title":"Sci Transl Med"},{"issue":"841","key":"2026080309063100200_fcag285-B48","doi-asserted-by":"crossref","first-page":"eadw2495","DOI":"10.1126\/scitranslmed.adw2495","article-title":"Lowering the HTT1a transcript as an effective therapy for Huntington\u2019s disease in a knockin mouse model","volume":"18","author":"Papadopoulou","year":"2026","journal-title":"Sci Transl Med"},{"issue":"6","key":"2026080309063100200_fcag285-B49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"2026080309063100200_fcag285-B50","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/brain\/awae266","article-title":"Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington\u2019s disease models","volume":"147","author":"Sogorb-Gonzalez","year":"2024","journal-title":"Brain"},{"issue":"12","key":"2026080309063100200_fcag285-B51","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/jnr.24493","article-title":"Phenotype onset in Huntington\u2019s disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene","volume":"97","author":"Franich","year":"2019","journal-title":"J Neurosci Res"},{"issue":"5","key":"2026080309063100200_fcag285-B52","doi-asserted-by":"crossref","first-page":"fcaf314","DOI":"10.1093\/braincomms\/fcaf314","article-title":"Mutant huntingtin exon 1 protein detected in mouse brain with neoepitope antibody: Effects of CAG repeat expansion, MutS Homolog 3 silencing and aggregation","volume":"7","author":"Sapp","year":"2025","journal-title":"Brain Commun"},{"issue":"1","key":"2026080309063100200_fcag285-B53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/hmg\/ddp467","article-title":"Identical oligomeric and fibrillar structures captured from the brains of R6\/2 and knock-in mouse models of Huntington\u2019s disease","volume":"19","author":"Sathasivam","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2026080309063100200_fcag285-B54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/18796397251404999","article-title":"Localization of mutant huntingtin with HTT Exon1 P90 C-terminal neoepitope antibodies in relation to regional and neuronal vulnerability in forebrain in Q175 mice and human Huntington\u2019s disease","volume":"15","author":"Deng","year":"2026","journal-title":"J Huntingtons Dis"},{"key":"2026080309063100200_fcag285-B55","doi-asserted-by":"publisher","author":"Murillo","DOI":"10.1101\/2024.02.19.580669"},{"key":"2026080309063100200_fcag285-B56","doi-asserted-by":"publisher","author":"Belgrad","DOI":"10.1101\/2025.06.24.661398"},{"issue":"4","key":"2026080309063100200_fcag285-B57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/nen.0b013e318040b2c8","article-title":"Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models","volume":"66","author":"Schilling","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026080309063100200_fcag285-B58","author":"Feng"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag285\/69526732\/fcag285.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag285\/69526732\/fcag285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag285\/69526732\/fcag285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:06:43Z","timestamp":1785762403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag285\/8737877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag285","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag285"}}